Why Millions of Non-Diabetics Are Wearing Continuous Glucose Monitors

For years, the small white patch worn on the back of the arm was a quiet, visible indicator of diabetes. Today, it has become the ultimate status symbol of the proactive health movement. Continuous glucose monitors (CGMs) have officially crossed over from prescription medical devices to mainstream wellness wearables, fundamentally changing how everyday people interact with their metabolism.[7]

The shift began in earnest in 2024 when the U.S. Food and Drug Administration cleared the first over-the-counter (OTC) continuous glucose monitors, including Dexcom's Stelo and Abbott's Lingo. Designed specifically for adults who do not use insulin, these devices removed the traditional barrier of a doctor's prescription. Almost overnight, the technology was opened to a massive new demographic of biohackers, athletes, and the "worried well" seeking to optimize their daily energy.[2][3]

The commercial impact of this regulatory shift has been staggering. Industry analysts note that the introduction of OTC devices expanded the total addressable market for CGMs from roughly 38 million traditional diabetic users to over 120 million potential wellness consumers globally. By 2026, the wellness-consumer CGM market is on track to become a multi-billion dollar industry, reshaping the portfolios of major medical technology firms.[5]

To understand the mainstream appeal, it helps to understand the mechanism. Unlike traditional fingerstick tests that require drawing blood, a CGM uses a microscopic, flexible filament inserted just beneath the skin. It measures glucose levels in the interstitial fluid—the fluid surrounding the body's cells—rather than the blood itself. The sensor continuously beams this data to a smartphone app, providing a 24/7 movie of a user's metabolism rather than a single, isolated snapshot.[1][7]

Historically, doctors have relied on fasting blood glucose and Hemoglobin A1c (HbA1c) tests to assess a patient's metabolic health. However, HbA1c only provides a three-month average. Longevity experts and functional medicine doctors argue that an average can mask dangerous glycemic variability—the extreme peaks and valleys in blood sugar that can drive cellular inflammation and precede clinical insulin resistance by years, or even decades.[1][2][7]

This is the core claim driving the OTC CGM boom: the need for absolute personalization. Clinical studies have increasingly demonstrated that two healthy individuals can have wildly different glycemic responses to the exact same meal. One person might experience a massive, prolonged glucose spike from a standard bowl of oatmeal, while another's blood sugar barely registers a change, dictated by factors like genetics, sleep debt, and their unique gut microbiome.[1][7]

Armed with real-time data, users can map their unique physiological responses without guessing. They can see in real-time how a brisk 15-minute walk after dinner blunts a glucose spike, or how a poor night of sleep elevates their baseline sugar levels the entire following day. For many users, watching a real-time graph climb into the red zone on their phone is a far more effective behavioral trigger than generic dietary advice to simply "eat less sugar."[1][3][7]

The consumer market is currently dominated by two distinct philosophies. Dexcom's Stelo, which boasts a 15-day wear time, is designed to track macro health trends and is heavily utilized by those with prediabetes or Type 2 diabetes who are not on insulin. It updates the user's app every 15 minutes, focusing on broad daily patterns rather than immediate, minute-by-minute micro-fluctuations.[3][4]

Conversely, Abbott's Lingo targets the habit-formation and pure wellness crowd. It streams data minute-by-minute and includes proprietary metrics designed to coach users through lifestyle changes, helping them identify specific stressors or foods that disrupt their metabolic balance. Both devices typically cost between $89 and $99 for a month's supply and are generally paid for out-of-pocket, as insurance rarely covers non-diabetic use.[3][4]

The medical establishment is beginning to adapt to this data-rich reality. In a landmark shift, the American Diabetes Association's 2025 Standards of Care formally incorporated OTC CGMs into its clinical guidance for non-insulin users. This policy validation signaled that continuous monitoring is no longer a fringe biohack, but a clinically reasonable practice for proactive health management and diabetes prevention.[4]

However, the trend is not without its vocal critics. Many endocrinologists warn against the rising culture of "toxic optimization," noting that a temporary rise in blood glucose after eating a carbohydrate-rich meal is a perfectly normal, healthy biological function. The human body is explicitly designed to process and clear these post-meal spikes without requiring intervention.[2][7]

There is growing concern that providing hyper-granular data to healthy individuals can trigger orthorexia—an unhealthy obsession with eating "pure" foods—or unnecessary anxiety over minor, harmless fluctuations. Critics argue that for someone without underlying metabolic dysfunction, striving for a perfectly flat glucose line is both biologically unnatural and psychologically exhausting, often leading people to abandon nutrient-dense foods like fruits and whole grains.[1][6]

Within the Type 1 diabetes community, reactions to the OTC boom remain mixed. Some advocates worry that marketing these devices for "habit formation" trivializes a life-saving medical device, comparing it to wearing a pacemaker for wellness tracking. Others, however, welcome the mainstreaming of the technology, noting that widespread adoption rapidly destigmatizes the devices, turning a visible marker of chronic illness into a normalized piece of everyday consumer tech.[6][7]

Despite the ongoing clinical debate, the trajectory of the technology is clear. As the Centers for Disease Control and Prevention estimates that nearly 100 million Americans have prediabetes—with the vast majority entirely unaware of their status—the shift toward accessible, real-time metabolic data represents a fundamental pivot. The era of guessing how food affects the body is officially over, replaced by an era of proactive, personalized health tracking.[7]